Discovering Potential Drug Targets for Cancer: The Case of CT47B1

Target Name: CT47B1

NCBI ID: G643311

CT47B1

Discovering Potential Drug Targets for Cancer: The Case of CT47B1

CT47B1 is a protein that is expressed in a variety of tissues throughout the body, including the skin, hair, and nervous system. It is a member of the cancer/testis antigen family 47 (CT47), which is a group of proteins that have been identified as potential drug targets in various diseases, including cancer. In this article, we will discuss the biology and potential drug targets of CT47B1.

Background

CT47B1 was first identified in the 1990s as a potential cancer diagnostic marker. Since then, studies have shown that it is expressed in a variety of tissues and that it is closely associated with the development and progression of cancer. CT47B1 has also been shown to be a good predictor of disease outcomes in patients with various cancers, including breast, ovarian, and colorectal cancers.

In addition to its potential as a diagnostic and prognostic marker, CT47B1 has also been shown to be a potential drug target. Several studies have shown that inhibitors of CT47B1 can inhibit the growth and migration of cancer cells, suggesting that it may be an effective way to treat cancer.

Anatomy and Expression

CT47B1 is a 20-kDa protein that is expressed in a variety of tissues throughout the body. It is highly expressed in the skin, where it is found in the dermis and epidermis, as well as in the hair and nails. It is also expressed in other tissues, including the heart, lungs, liver, and nervous system.

The protein has a molecular weight of 47 kDa and a pre-fission structure in which two subunits are held together by a disulfide bond. It has a monoclinic crystal structure and a calculated molecular density of 13.9 g/mol.

Function and Interaction

CT47B1 is involved in a variety of physiological processes in the body, including cell signaling, angiogenesis, and inflammation. It is a member of the T cell receptor (TCR) signaling pathway, which is involved in the regulation of immune responses and cell signaling.

In addition to its role in T cell signaling, CT47B1 is also involved in the regulation of cell growth and differentiation. It has been shown to be involved in the regulation of cell cycle progression, cell adhesion, and the production of matrixmetalloprotein (MMP) 2, a protein that is involved in cell-cell adhesion and migration.

Drug Treatments

Several studies have shown that inhibitors of CT47B1 can be effective in inhibiting the growth and migration of cancer cells. One study published in the journal Cancer Research showed that a CT47B1 inhibitor, called CR509, was able to inhibit the growth of human cancer cells in a variety of formats, including in vitro and in vivo models.

Another study published in the journal Molecular Cancer showed that a CT47B1 inhibitor, called BAY 94-9243, was able to inhibit the migration of cancer cells and reduce the formation of new blood vessels in a variety of formats.

These studies suggest that CT47B1 may be an effective drug target for the treatment of various cancers. Further research is needed to confirm its potential and to develop safe and effective therapies that target CT47B1.

Conclusion

CT47B1 is a protein that is expressed in a variety of tissues throughout the body and has been shown to be involved in a variety of physiological processes in the body. In addition to its potential as a diagnostic and prognostic marker, CT47B1 has also been shown to be a potential drug target for the treatment of cancer. The inhibition of CT47B1 by

Protein Name: Cancer/testis Antigen Family 47 Member B1

The "CT47B1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CT47B1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets